ArticleArteriosclerosis, thrombosis, and vascular biology2014
Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis.Journal of the American Heart Association · 2018Pooled it
- Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.Cardiovascular diabetology · 2015Trial
- Skin autofluorescence is associated with plasma levels of matrix metalloproteinases in subjects without overt atherosclerosis.Vascular medicine (London, England) · 2026Article
- Skin levels of advanced glycation end products in correlation with periodontal conditions - a pilot study.BMC oral health · 2026Article
- Association between skin autofluorescence and all-cause mortality, cardiovascular mortality and cardiovascular disease: a systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Review
- Association Between Skin Autofluorescence and Coronary Heart Disease in Chinese General Population: A Cross-Sectional Study.Journal of diabetes · 2025Article
- The roles of advanced glycation end products in cardiovascular diseases: from mechanisms to therapeutic strategies.Frontiers in cardiovascular medicine · 2025Review
- Skin autofluorescence and cause-specific mortality in a population-based cohort.Scientific reports · 2024Article
- Skin Autofluorescence and Clinical Outcomes in Patients with Coronary Artery Disease.Journal of atherosclerosis and thrombosis · 2024Article
- Metabolic memory: mechanisms and diseases.Signal transduction and targeted therapy · 2024Review
- Subcutaneous advanced glycation end products, cardiovascular risk factors and vascular health during childhood development in a Swiss population.Frontiers in physiology · 2024Article
- Non-contact measurement of neck pulses achieved by imaging micro-motions in the neck skin.Biomedical optics express · 2023Article
- Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies.Nutrients · 2023Review
- Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.Breast cancer research and treatment · 2022Article
- Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.Nutrients · 2022Review
- Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus.Heliyon · 2022Article
- A physically active lifestyle is related to a lower level of skin autofluorescence in a large population with chronic-disease (LifeLines cohort).Journal of sport and health science · 2022Article
- Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes.BMC endocrine disorders · 2021Article
- Skin autofluorescence, a marker of glucose memory in type 2 diabetes.Metabolism open · 2020Article
- The Nitric Oxide System in Peripheral Artery Disease: Connection with Oxidative Stress and Biopterins.Antioxidants (Basel, Switzerland) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAdvanced glycation end products play a pivotal role in atherosclerosis. Recently, we showed that tissue advanced glycation end products deposition, noninvasively assessed by skin autofluorescence (SAF), is increased in patients with peripheral artery disease. The aim of the present study was to establish whether SAF is associated with all-cause mortality and with fatal or nonfatal major adverse cardiovascular events (MACE) in patients with peripheral artery disease. APPROACH AND
resultsWe performed a single-center prospective cohort study of 252 patients with peripheral artery disease (mean age, 66±11 years), recruited from the outpatient clinic (October 2007 to June 2008) who were followed until June 2013. SAF was measured with the AGE Reader. The primary end point was all-cause mortality, and the secondary end point was fatal or nonfatal MACE, defined as cardiovascular death and nonfatal myocardial infarction or stroke. During a median follow-up of 5.1 (interquartile range, 5.0-5.3) years, 62 (25%) patients died. Fatal or nonfatal MACE occurred in 62 (25%) patients. A higher SAF was associated with increased risk for all-cause mortality (hazard ratio per unit increase, 2.01; 95% confidence interval, 1.40-2.88; P=0.0002) and fatal or nonfatal MACE (hazard ratio, 1.82; 95% confidence interval, 1.28-2.60; P=0.001), also after adjustment for cardiovascular risk factors and the use of lipid-lowering drugs (hazard ratio, 1.63; 95% confidence interval, 1.13-2.34; P=0.009 and hazard ratio, 1.50; 95% confidence interval, 1.04-2.17; P=0.03, for all-cause mortality and fatal and nonfatal MACE, respectively).
conclusionsSAF as a measure of advanced glycation end products deposition is independently associated with all-cause mortality and fatal or nonfatal MACE in patients with peripheral artery disease after a 5-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.